focus -WSS

focus

author：leisure time 2025-10-02 17:21:48 - browse：9116

Business standing in the middle of a maze near a bag with a dollar sign on it. -- biotech coverage from STAT — Adobe

Over the last year or two, something curious has started occurring in the conference rooms and private Zoom meetings of biotech venture capitalists.

Representatives from pension funds, college endowments, family offices, and other organizations with money to invest have become bolder in their requests, according to interviews with a host of VCs. They’re pushing not only for advantageous terms in a VC firm’s latest fund, but in some cases, have angled for equity in the firm itself. These types of conditions aren’t unheard of, but have become more frequent as venture capitalists have a harder time raising funds, and as outside investors feel empowered to ask for more bang for their buck.

“A lot is changing in venture fundraising right now,” said Nan Li, co-founder and managing partner of Dimension, which launched last January. Outside investors tried to ask for a piece of Dimension, but the new firm had more than enough interest in its first fund and was able to turn down those proposals. Two other young VC firms told STAT they’ve fielded similar requests, and one investment group reported that it had managed to negotiate an equity stake in a VC firm.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Readout Newsletter: What happened with Sarepta's Duchenne data

leisure time

focus

WSS

Maker of FluMist seeks to allow at

Cassava reveals details — and problems — with Alzheimer's study

Chemotherapy drug shortage eases slightly but still widespread

Maker of FluMist seeks to allow at

First Opinion Podcast: How to protect health care in times of war

Chemotherapy drug shortage eases slightly but still widespread

focus

focus

Wikipedia

Affirmative action in medical school literally saved lives

Meta's Zuckerberg and Chan on track to put $50 billion into science

Dobbs anniversary: the lost opportunity of abortion as health care

Eli Lilly to pay $200M for Beam’s stake in gene

Dobbs anniversary: the lost opportunity of abortion as health care

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Tori Bowie and the unacceptable rates of Black maternal death

Readout Newsletter: What happened with Sarepta's Duchenne data

Novavax promises a turnaround & Lilly roils the obesity market

WHO may add ‘noma' to its list of neglected tropical diseases

hotspot

Senate panel eyes new effort on drug shortages

Why age limits for politicians are a terrible idea

The pink breast cancer awareness ribbon needs a redesign

FDA panel signals lack of confidence in Amgen cancer drug data

Physician executives need more than on

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

leisure time

knowledge

focus

knowledge